Your browser is no longer supported. Please, upgrade your browser.
Settings
CRL Charles River Laboratories International, Inc. daily Stock Chart
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E27.06 EPS (ttm)4.31 Insider Own1.70% Shs Outstand47.79M Perf Week0.60%
Market Cap5.57B Forward P/E17.86 EPS next Y6.53 Insider Trans-18.20% Shs Float47.10M Perf Month11.01%
Income207.90M PEG2.18 EPS next Q1.47 Inst Own99.95% Short Float3.00% Perf Quarter5.14%
Sales1.91B P/S2.92 EPS this Y29.10% Inst Trans-0.33% Short Ratio4.45 Perf Half Y11.14%
Book/sh23.85 P/B4.89 EPS next Y11.84% ROA4.50% Target Price115.85 Perf Year21.72%
Cash/sh3.98 P/C29.27 EPS next 5Y12.40% ROE12.40% 52W Range94.15 - 119.05 Perf YTD6.50%
Dividend- P/FCF22.47 EPS past 5Y14.70% ROI8.90% 52W High-2.68% Beta0.68
Dividend %- Quick Ratio1.80 Sales past 5Y10.50% Gross Margin37.40% 52W Low23.06% ATR2.03
Employees11800 Current Ratio2.10 Sales Q/Q10.80% Oper. Margin15.00% RSI (14)67.46 Volatility1.75% 1.58%
OptionableYes Debt/Eq0.99 EPS Q/Q11.60% Profit Margin6.80% Rel Volume0.42 Prev Close116.56
ShortableYes LT Debt/Eq0.99 EarningsMay 10 BMO Payout0.00% Avg Volume317.34K Price115.86
Recom2.30 SMA204.89% SMA507.80% SMA2007.40% Volume88,299 Change-0.60%
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Feb-14-18Upgrade SunTrust Hold → Buy
Jan-22-18Downgrade SunTrust Buy → Hold
Jan-19-18Initiated Evercore ISI In-line $117
Dec-13-17Initiated Argus Buy $120
Sep-19-17Initiated RBC Capital Mkts Sector Perform $110
Dec-16-16Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade Barclays Underweight → Equal Weight $65 → $77
Sep-06-16Downgrade UBS Neutral → Sell $83 → $78
Jun-21-16Initiated Credit Suisse Neutral $84
May-20-16Reiterated Barclays Underweight $60 → $65
Apr-26-16Initiated Gabelli & Co Buy $96
Jan-07-16Upgrade Wells Fargo Market Perform → Outperform
Oct-12-15Upgrade Wells Fargo Underperform → Market Perform
Jul-31-15Reiterated Deutsche Bank Hold $76 → $79
Jul-10-15Upgrade BofA/Merrill Neutral → Buy $76 → $83
Jul-10-15Downgrade Barclays Equal Weight → Underweight $60
May-04-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $88
Apr-24-15Reiterated Barclays Equal Weight $55 → $60
Feb-12-15Reiterated Deutsche Bank Hold $63 → $77
Jun-15-18 09:23AM  Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade Benzinga
Jun-04-18 04:30PM  Charles River Laboratories to Present at Jefferies and William Blair Conferences Business Wire
May-29-18 01:49PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Charles River Laboratories International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
May-15-18 01:51AM  Edited Transcript of CRL earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-10-18 07:12AM  Charles River: 1Q Earnings Snapshot Associated Press
07:00AM  Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations Business Wire
May-09-18 09:00AM  Should You Buy Charles River Laboratories (CRL) Before Earnings? Zacks
May-03-18 08:00AM  Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation Business Wire
May-01-18 08:00AM  Charles River Laboratories Expands Services for Early Discovery Screening Business Wire
Apr-12-18 04:30PM  Charles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference Call Business Wire
Apr-10-18 01:22PM  Edited Transcript of CRL presentation 7-Mar-17 6:05pm GMT Thomson Reuters StreetEvents
08:00AM  Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018 Business Wire
Apr-09-18 08:00AM  Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership Business Wire
Apr-03-18 08:30AM  Charles River Laboratories Completes the Acquisition of MPI Research Business Wire
08:30AM  Charles River Laboratories Announces Closing of Senior Notes Offering Business Wire
Mar-26-18 10:20AM  Charles River Laboratories Int'l, Inc. -- Moody's assigns B1 to Charles River's unsecured notes; secured term loan upgraded to Ba1 Moody's
08:00AM  Charles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior Notes Business Wire
Mar-08-18 08:00AM  Charles River Laboratories Makes Expansions to Global Biologics Infrastructure Business Wire
Mar-05-18 08:00AM  Charles River Laboratories to Present at Raymond James and Barclays Conferences Business Wire
Mar-01-18 02:11PM  With A -20.00% Earnings Drop Lately, Did Charles River Laboratories International Inc (NYSE:CRL) Underperform Its Industry? Simply Wall St.
Feb-21-18 08:00AM  Charles River Laboratories Announces New Tumor Model Compendium Business Wire
Feb-16-18 07:40AM  Market Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-15-18 07:30AM  Wired News Charles River Labs Inked an Agreement to Acquire MPI Research ACCESSWIRE
Feb-13-18 07:08PM  Charles River Laboratories Int'l, Inc. -- Moody's affirms Charles River's Ba2 CFR; outlook stable Moody's +5.56%
05:47PM  Edited Transcript of CRL earnings conference call or presentation 13-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
11:05AM  Charles River Labs to acquire contract research firm for $800M American City Business Journals
07:29AM  Charles River reports 4Q loss Associated Press
07:02AM  Charles River Laboratories Announces Executive Management Appointments Business Wire
07:01AM  Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance Business Wire
07:00AM  Charles River Laboratories to Acquire MPI Research Business Wire
Feb-09-18 08:55AM  Should You Buy Charles River Laboratories (CRL) Ahead of Earnings? Zacks
Feb-01-18 08:00AM  Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure Business Wire
Jan-25-18 04:30PM  Charles River Laboratories Schedules Fourth-Quarter 2017 Earnings and 2018 Guidance Release and Conference Call Business Wire
Jan-17-18 11:01AM  IIROC Trade Resumption - CRL, CRL.WT, CRL.RT PR Newswire
09:14AM  IIROC Trading Halt - CRL CRL.WT CRL.RT PR Newswire
Jan-16-18 08:00AM  Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors Business Wire
Jan-15-18 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Jan-12-18 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Jan-11-18 07:00AM  Charles River Laboratories Acquires KWS BioTest Business Wire
Jan-09-18 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Jan-08-18 11:19AM  Carl Data Solutions Announces Completion of Rights Offering CNW Group
08:00AM  Charles River Laboratories to Present at J.P. Morgan Healthcare Conference Business Wire
Dec-26-17 07:50AM  Free Post Earnings Research Report: Charles Rivers Revenue Grew 9%; EPS Surged 36.7% ACCESSWIRE
Dec-21-17 07:05AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish Manner : CRL-US : December 21, 2017 Capital Cube
Dec-13-17 03:00AM  Charles River Labs International Sees IBD RS Rating Rise To 72 Investor's Business Daily
Dec-11-17 01:44PM  ETFs with exposure to Charles River Laboratories International, Inc. : December 11, 2017 Capital Cube
Dec-08-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Dec-07-17 03:26PM  First Solar Flys Higher, Charles River Labs Flows In Reverse Forbes
Dec-06-17 08:00AM  Charles River Adds ERS License to CRISPR/Cas9 Service Offering Business Wire
Dec-01-17 10:34AM  ETFs with exposure to Charles River Laboratories International, Inc. : December 1, 2017 Capital Cube
08:00AM  Investor Expectations to Drive Momentum within CatchMark Timber Trust, Global Payments, Charles River Laboratories International, Tile Shop Hldgs, Cytokinetics, and Limelight Networks Discovering Underlying Factors of Influence GlobeNewswire
Nov-28-17 08:00AM  Charles River Announces Success of Integrated Discovery Project with ENYO Pharma Business Wire
Nov-20-17 12:04PM  ETFs with exposure to Charles River Laboratories International, Inc. : November 20, 2017 Capital Cube
Nov-17-17 08:06AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Nov-15-17 07:13PM  Cramer's lightning round: Don't buy Mallinckrodt after it... CNBC Videos
06:49PM  Cramer's lightning round: Sell Mallinckrodt after its 'nutty' acquisition of Acthar CNBC
09:36AM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 15, 2017 Capital Cube
Nov-14-17 08:06AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
07:20AM  Earnings Review and Free Research Report: Labcorps Revenue Jumped 9.5%; Raised Outlook for 2017 ACCESSWIRE
Nov-13-17 01:57PM  Charles River Laboratories International, Inc. Value Analysis (NYSE:CRL) : November 13, 2017 Capital Cube
06:44AM  Edited Transcript of CRL earnings conference call or presentation 9-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 07:29AM  Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : November 10, 2017 Capital Cube
Nov-09-17 12:26PM  ETFs with exposure to Charles River Laboratories International, Inc. : November 9, 2017 Capital Cube -12.69%
11:45AM  What Should You Know About Charles River Laboratories International Incs (CRL) Future? Simply Wall St.
07:15AM  Charles River tops Street 3Q forecasts Associated Press
07:00AM  Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations Business Wire
Nov-08-17 08:50AM  Why Earnings Season Could Be Great for Charles River Laboratories (CRL) Zacks
Nov-01-17 08:00AM  Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017 Business Wire
Oct-26-17 08:00AM  Charles River Announces Expansion of In Vitro Oncology Services Business Wire
Oct-23-17 02:10PM  Charles River Laboratories Intl. Inc Can Keep the Run Going InvestorPlace
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-13-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-12-17 04:30PM  Charles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference Call Business Wire
Oct-11-17 04:30PM  Charles River Laboratories Schedules Third-Quarter 2017 Earnings Release and Conference Call Business Wire
08:04AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-10-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-09-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-06-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-05-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Oct-02-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-27-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-25-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-20-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-18-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-15-17 08:01AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-14-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Sep-12-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
08:00AM  Charles River Research Models in Drug Discovery Award Presented to Sonia Vallabh and Eric Minikel of the Prion Alliance Business Wire
Sep-05-17 08:00AM  Charles River Laboratories to Present at September Investor Conferences Business Wire
Sep-01-17 07:20AM  Earnings Review and Free Research Report: Charles Rivers Q2 Results Outshined Market Expectations ACCESSWIRE
Aug-31-17 08:08AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-30-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-29-17 08:00AM  Distinguished Industry Leaders Join Lineup for Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development Business Wire
Aug-24-17 03:09PM  ETFs with exposure to Charles River Laboratories International, Inc. : August 24, 2017 Capital Cube
Aug-23-17 08:02AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-22-17 08:03AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-18-17 12:30PM  Carl Data Solutions Announces Private Placement in Support of New Productivity Features for Applications GlobeNewswire
Aug-17-17 08:04AM  See what the IHS Markit Score report has to say about Charles River Laboratories International Inc. Markit
Aug-15-17 08:22AM  Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development to Explore Trends in Reverse Translational Medicine Business Wire
Aug-14-17 12:04PM  Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 14, 2017 Capital Cube
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MASSARO GEORGEDirectorMay 14Sale107.191,218130,55813,837May 15 04:09 PM
Smith David RossCorporate Executive VP & CFOMay 01Option Exercise51.4594548,62013,723May 03 08:44 AM
Smith David RossCorporate Executive VP & CFOMay 01Sale104.2394598,49912,778May 03 08:44 AM
MILNE GEORGE M JRDirectorMar 09Option Exercise40.277,740311,69036,760Mar 13 11:43 AM
MILNE GEORGE M JRDirectorMar 09Sale115.007,740890,10029,020Mar 13 11:43 AM
FOSTER JAMES CChairman & CEOMar 06Option Exercise88.0524,0082,113,904325,684Mar 07 04:56 PM
Girshick BirgitCorporate Executive VPMar 06Option Exercise79.277,313579,69432,870Mar 07 04:52 PM
FOSTER JAMES CChairman & CEOMar 06Sale110.0024,0082,640,880301,676Mar 07 04:56 PM
Girshick BirgitCorporate Executive VPMar 06Sale109.109,8931,079,34322,977Mar 07 04:52 PM
Smith David RossCorporate Executive VP & CFOFeb 28Option Exercise88.054,365384,33818,443Mar 02 11:04 AM
FOSTER JAMES CChairman & CEOFeb 28Option Exercise59.4120,0721,192,478324,012Mar 02 07:25 AM
FOSTER JAMES CChairman & CEOFeb 28Sale108.035,102551,176310,440Mar 02 07:30 AM
FOSTER JAMES CChairman & CEOFeb 28Sale107.393,372362,113320,640Mar 02 07:25 AM
Smith David RossCorporate Executive VP & CFOFeb 28Sale108.4310010,84313,103Mar 02 11:06 AM
Smith David RossCorporate Executive VP & CFOFeb 28Sale107.905,240565,41413,203Mar 02 11:04 AM
FOSTER JAMES CChairman & CEOFeb 28Sale108.472,102227,995303,940Mar 02 07:34 AM
FOSTER JAMES CChairman & CEOFeb 28Sale108.244,398476,046306,042Mar 02 07:32 AM
FOSTER JAMES CChairman & CEOFeb 28Sale107.815,098549,639315,542Mar 02 07:28 AM
FOSTER JAMES CChairman & CEOFeb 27Option Exercise76.7021,5771,654,956325,517Mar 01 12:11 PM
Smith David RossCorporate Executive VP & CFOFeb 27Option Exercise76.672,158165,45416,236Mar 01 12:50 PM
Smith David RossCorporate Executive VP & CFOFeb 27Sale108.102,158233,28314,078Mar 01 12:50 PM
FOSTER JAMES CChairman & CEOFeb 27Sale108.157,067764,280308,647Mar 01 12:35 PM
FOSTER JAMES CChairman & CEOFeb 27Sale107.915,993646,703315,714Mar 01 12:15 PM
FOSTER JAMES CChairman & CEOFeb 27Sale108.414,707510,282303,940Mar 01 12:39 PM
FOSTER JAMES CChairman & CEOFeb 27Sale107.663,810410,199321,707Mar 01 12:11 PM
Smith David RossCorporate Executive VP & CFOFeb 26Option Exercise73.704,187308,58218,483Feb 28 07:12 AM
FOSTER JAMES CChairman & CEOFeb 26Option Exercise73.7025,1241,851,639331,238Feb 28 03:12 PM
Smith David RossCorporate Executive VP & CFOFeb 26Sale107.353,868415,22414,615Feb 28 07:12 AM
FOSTER JAMES CChairman & CEOFeb 26Sale107.855,269568,287311,443Feb 28 03:30 PM
FOSTER JAMES CChairman & CEOFeb 26Sale108.8190097,929306,114Feb 28 03:40 PM
FOSTER JAMES CChairman & CEOFeb 26Sale108.434,429480,232307,014Feb 28 03:39 PM
FOSTER JAMES CChairman & CEOFeb 26Sale107.005,727612,779320,711Feb 28 03:15 PM
FOSTER JAMES CChairman & CEOFeb 26Sale106.694,800512,123326,438Feb 28 03:12 PM
Smith David RossCorporate Executive VP & CFOFeb 26Sale108.5331934,62014,296Feb 28 07:16 AM
FOSTER JAMES CChairman & CEOFeb 26Sale107.313,999429,135316,712Feb 28 03:25 PM
Barbo William DCorporate Executive VP & CCOFeb 21Sale108.082,320250,74119,156Feb 22 11:14 AM
Smith David RossCorporate Executive VP & CFOFeb 16Sale109.073,639396,89911,671Feb 20 02:45 PM
CHUBB STEPHEN DDirectorFeb 15Option Exercise40.277,740311,69036,461Feb 16 08:30 AM
FOSTER JAMES CChairman, President and CEOFeb 15Sale107.50464,94529,954Feb 20 02:38 PM
CHUBB STEPHEN DDirectorFeb 15Sale108.702,872312,17233,589Feb 16 08:30 AM
Smith David RossCorporate Executive VP & CFOJan 02Option Exercise51.4516,817865,23528,488Jan 03 03:52 PM
BERTOLINI ROBERT JDirectorJan 02Option Exercise40.277,740311,69030,326Jan 03 04:11 PM
BERTOLINI ROBERT JDirectorJan 02Sale109.594,131452,71726,195Jan 03 04:11 PM
FOSTER JAMES CChairman, President and CEOJan 02Sale109.444,967543,590315,299Jan 04 11:09 AM
Smith David RossCorporate Executive VP & CFOJan 02Sale110.383,100342,19111,671Jan 03 03:56 PM
FOSTER JAMES CChairman, President and CEOJan 02Sale110.313,465382,229295,266Jan 04 11:17 AM
FOSTER JAMES CChairman, President and CEOJan 02Sale110.169,2461,018,558298,731Jan 04 11:15 AM
BERTOLINI ROBERT JDirectorJan 02Sale110.223,609397,78522,586Jan 03 04:14 PM
Smith David RossCorporate Executive VP & CFOJan 02Sale110.018,231905,49714,771Jan 03 03:54 PM
Smith David RossCorporate Executive VP & CFOJan 02Sale109.535,486600,89123,002Jan 03 03:52 PM
FOSTER JAMES CChairman, President and CEOJan 02Sale109.787,322803,823307,977Jan 04 11:12 AM
REESE C RICHARDDirectorDec 06Option Exercise45.5122,9801,045,88866,684Dec 08 10:06 AM
REESE C RICHARDDirectorDec 06Sale102.4010,2271,047,24556,457Dec 08 10:06 AM
JOHST DAVID PCorporate Executive VPOct 05Option Exercise40.4024,7591,000,264206,014Oct 06 12:21 PM
Molho DavideCorporate Executive VPOct 05Option Exercise76.676,165472,67122,714Oct 06 12:17 PM
JOHST DAVID PCorporate Executive VPOct 05Sale110.0024,7592,723,490181,255Oct 06 12:21 PM
Molho DavideCorporate Executive VPOct 05Sale110.006,165678,15016,549Oct 06 12:17 PM
Molho DavideCorporate Executive VPSep 05Option Exercise74.9614,5391,089,83431,088Sep 07 08:50 AM
Molho DavideCorporate Executive VPSep 05Sale108.065,889636,34719,217Sep 07 08:51 AM
Molho DavideCorporate Executive VPSep 05Sale107.555,982643,37325,106Sep 07 08:50 AM
Molho DavideCorporate Executive VPSep 05Sale108.432,668289,29716,549Sep 07 08:53 AM
Barbo William DCorporate Executive VP & CCOAug 17Sale99.914,000399,63216,924Aug 21 06:42 AM
Smith David RossCorporate Executive VP & CFOAug 14Option Exercise76.121,24995,07412,920Aug 16 08:02 AM
Smith David RossCorporate Executive VP & CFOAug 14Sale67.102,552171,22811,671Aug 16 08:02 AM
MASSARO GEORGEDirectorJul 17Option Exercise43.394,030174,86218,731Jul 18 12:51 PM
MASSARO GEORGEDirectorJul 17Sale100.813,830386,10314,901Jul 18 12:51 PM
MASSARO GEORGEDirectorJul 17Sale101.3820020,27614,701Jul 18 01:04 PM
FOSTER JAMES CChairman, President and CEOJul 10Sale100.0250050,008336,178Jul 12 07:15 AM
FOSTER JAMES CChairman, President and CEOJul 10Sale99.079,264917,818342,398Jul 12 07:11 AM
FOSTER JAMES CChairman, President and CEOJul 10Sale98.929,516941,337351,662Jul 12 07:09 AM
FOSTER JAMES CChairman, President and CEOJul 10Sale99.305,720568,011336,678Jul 12 07:13 AM
Molho DavideCorporate Executive VPJun 22Option Exercise59.4110,948650,42127,497Jun 23 10:39 AM
FOSTER JAMES CChairman, President and CEOJun 22Option Exercise76.6743,1543,308,617404,332Jun 23 02:03 PM
FOSTER JAMES CChairman, President and CEOJun 22Sale100.0043,1544,315,400361,178Jun 23 02:03 PM
Molho DavideCorporate Executive VPJun 22Sale100.0010,9481,094,80016,549Jun 23 10:39 AM